

| Ludwig Scientist(s) | Affiliation(s) | Session Time | Presentation Time | Location | Session Type | Session Title | Presentation/Abstract Title |
|---|-------------------------------|---------------------|---------------------------------------|--------------------------------|--|---|--|
| Friday, March 29 | | | | | | | |
| Michael A. Postow | Ludwig MSK | 5:15 - 7:15 PM | 5:15 - 5:40 PM | Room A411 - Georgia World CC | Education Session | ED37 - Intersection of Radiation and Immune Therapy | Clinical experience with radiotherapy in the context of immune checkpoint blockade |
| Saturday, March 30 | | | | | | | |
| Kornelia Polyak* | Ludwig Harvard | 8:00 - 10:00 AM | 8:00 AM - 10:00 AM | Marcus Auditorium- Bldg A-GWCC | Education Session | ED43 - Co-evolution of Tumor and Microenvironment in Cancer Metastasis | Chairperson and Mechanisms underlying polyclonal metastases |
| Rakesh K. Jain* | Ludwig Harvard | 8:00 - 10:00 AM | 8:00 AM - 8:25 AM | Room A411 - Georgia World CC | Education Session | ED10 - Vascular-Immune Cell Crosstalk: Implications for Cancer Immunotherapy | Improving immunotherapy of cancer by normalizing tumor vessels |
| Tatiana Petrova | Ludwig Lausanne | 8:00 - 10:00 AM | 9:00 - 9:45 AM | Room A411 - Georgia World CC | Education Session | ED10 - Vascular-Immune Cell Crosstalk: Implications for Cancer Immunotherapy | Targeting the tumor microenvironment for treatment of chemo-resistant desmoplastic colon cancer |
| Matthew G. Vander Heiden | Ludwig MIT | 10:15 AM - 12:15 PM | 10:15 - 10:16 AM and 10:15 - 10:35 AM | Georgia Ballrm 1- Bldg C-GWCC | Methods Workshop | MW13 - Methods to Study Metabolism for Cancer Research | Chairperson and Importance of tissue context in understanding metabolic vulnerabilities |
| Nickolas Papadopoulos | Ludwig Johns Hopkins | 3:15 - 5:15 PM | 3:15 - 3:40 PM | Room B312 - Georgia World CC | Education Session | ED28 - ctDNA for Cancer Stratification, Monitoring, Clonal Tracking, MRD Detection, and Early Diagnosis | ctDNA and cfDNA in body fluids as cancer biomarkers |
| Sunday, March 31 | | | | | | | |
| Pier Paolo Pandolfi* | Ludwig Harvard | 7:00 - 8:00 AM | 7:00 AM - 8:00 AM | Room A311 - Georgia World CC | Meet-the-Expert Session | ME41 - Title to Be Announced | Title to be announced |
| Crystal L. Mackall | Ludwig Stanford | 9:45 AM - 12:15 PM | 11:15 - 11:40 AM | Hall A - Convention Center | Plenary Session | PL01 - Opening Plenary: Achieving Equitable Patient Care through Precision and Convergent Cancer Science | PL01-05 - Next-generation CAR T cells designed to overcome tumor resistance |
| Peter K. Sorger | Ludwig Harvard | 2:00 - 3:30 PM | 2:10 PM - 2:25 PM | Room A406 - Georgia World CC | NCI/NIH-Sponsored Session | NIH03 - Towards the Generation of Spatial Human Tumor Maps | Molecular and spatial characterization of human tumors: Multiplexed protein imaging in intact tissue sections using CycIF |
| Joan S. Brugge** | Ludwig Harvard | 3:00 - 5:00 PM | 3:35 PM - 3:50 PM | Room A404 - Georgia World CC | Minisymposium | MS.TB02.01 - Novel Approaches to Understand Cancer Stem Cells | 969 - Characterization of murine mammary epithelial populations throughout development and in premalignant tissue via mass cytometry |
| Cigall Kadoch | Ludwig Harvard | 3:00 - 5:00 PM | 3:35 PM - 3:50 PM | Room B206 - Georgia World CC | Minisymposium | MS.BSB01.01 - Tools for Cancer Genome Analysis | 907 - Bioinformatic method to define epigenetically regulated enhancer elements associated with cancer |
| Chris Sander | Ludwig Harvard | 3:00 - 5:00 PM | 4:20 PM - 4:35 PM | Room B206 - Georgia World CC | Minisymposium | MS.BSB01.01 - Tools for Cancer Genome Analysis | 910 - The cBioPortal for cancer genomics |
| Cigall Kadoch | Ludwig Harvard | 3:00 - 5:00 PM | 3:35 PM - 3:50 PM | Room A302 - Georgia World CC | Minisymposium | MS.MCB05.01 - Emerging Targets in Cancer Epigenetics | 949 - ARID1A is a critical regulator of luminal identity and therapeutic response in estrogen receptor-positive breast cancer |
| F. Stephen Hodi, Jedd D. Wolchok | Ludwig Harvard and Ludwig MSK | 3:00 - 5:00 PM | 3:00 - 5:00 PM | Room A411 - Georgia World CC | Clinical Trials Minisymposium | CTMS01 - Advances in Novel Immunotherapeutics | CT037 - Genomic analyses and immunotherapy in advanced melanoma |
| Andrew Chow*, Sadna Budhu, Hong Zhong, Jason S. Lewis, Jedd D. Wolchok**, Taha Merghoub** | Ludwig MSK | 3:00 - 5:00 PM | 3:00 - 5:00 PM | Room B312 - Georgia World CC | Minisymposium | MS.TB06.01 - The Immune Microenvironment in Cancer | 978 - Tim-4+ tissue-resident macrophages impair antitumor T-cell immunity |
| Chi Van Dang* | The Ludwig Institute | 4:00 - 5:00 PM | 4:00 PM - 5:00 PM | AACR Pubs Booth 3226 - Hall B | Meet and Greet | MG06 - Meet the Editor-in-Chief of Cancer Research: Chi Van Dang, MD, PhD | Invited Speaker |
| Jedd D. Wolchok | Ludwig MSK | 5:00 - 7:00 PM | 5:00 - 7:00 PM | International Ballrm N - Hyatt | Professional Advancement Session | PAS06 - Personalized Career Conversations: Pathways to Academia, Industry, and Government | Mentor |
| Crystal L. Mackall | Ludwig Stanford | 6:30 - 8:30 PM | 6:30 - 8:30 PM | Town Meeting | Town Meeting | TM06 - Pediatric Cancer Working Group (PCWG) Town Hall Meeting and Networking Reception | Chairperson and Moderator |
| Monday, April 1 | | | | | | | |
| Peter K. Sorger | Ludwig Harvard | 7:00 - 8:00 AM | 7:00 AM - 8:00 AM | Room B302 - Georgia World CC | Meet-the-Expert Session | ME48 - Approaches to Combination Therapy | Approaches to combination therapy |
| Myles Brown | Ludwig Harvard | 10:30 AM - 12:15 PM | 11:05 AM - 11:30 AM | Room B405 - Georgia World CC | Major Symposium | SY43 - Systems Epigenetics in Hormone-Driven Cancers | Cistrome mining for new therapeutic targets in hormone-dependent cancers |
| Chi Van Dang* | The Ludwig Institute | 10:30 AM - 12:15 PM | 10:35 AM - 11:00 AM | Room B401 - Georgia World CC | Major Symposium | SY37 - Circadian Rhythms and Cancer | MYC, clock function, and metabolic vulnerabilities of cancer |
| Nancy E. Davidson* | Ludwig Board of Directors | 1:00 - 2:45 PM | 1:05 PM - 1:30 PM | Room A313 - Georgia World CC | Major Symposium | SY48 - Women in Cancer Research Scientific Symposium: Advances in Genetics, Diagnosis, and Therapeutics among Common Cancers in Women | Invited Speaker |
| Joan S. Brugge | Ludwig Harvard | 1:00 - 2:45 PM | 1:00 - 1:01 PM and 1:00 - 1:25 PM | Georgia Ballrm 1- Bldg C-GWCC | Advances in Diagnostics and Therapeutics | ADT11 - Clonal Cooperation in Cancer | Chairperson and Transient commensalism drives solid peritoneal metastasis in a model of ovarian clear cell carcinoma |
| Benjamin Izar*, F. Stephen Hodi, Peter K. Sorger, Asaf Rotem | Ludwig Harvard | 1:00 - 2:45 PM | 1:55 PM - 2:10 PM | Marcus Auditorium- Bldg A-GWCC | Major Symposium | SY45-313 - The Next Generation of Precision Cancer Medicine: Recognizing and Exploiting the Complexity | SY45-04 - Development of therapeutic strategies by resolving the tumor ecosystem |
| Franziska Michor* | Ludwig Harvard | 1:00 - 2:45 PM | 2:05 PM - 2:30 PM | Murphy Ballrm- Bldg B- GWCC | Major Symposium | SY38 - Evolution and Development of Resistance to Therapy | From evolutionary mathematical modeling to clinical validation in glioblastoma patients: Lessons learned |
| Michael F. Clarke | Ludwig Stanford | 1:00 - 2:45 PM | 1:35 - 2:00 PM | Room B206 - Georgia World CC | Major Symposium | SY17 - Minimal Residual Disease: From Bench to Bedside | SY17-02 - Solid tumor cancer stem cells: From bench to bedside |
| Crystal L. Mackall | Ludwig Stanford | 1:00 - 2:45 PM | 1:00 - 1:01 PM | Georgia Ballrm 3- Bldg C-GWCC | Advances in Organ Site Research | AOS02 - Emerging Immunotherapies for Childhood Cancer | Chairperson |
| Franziska Michor, Kornelia Polyak** | Ludwig Harvard | 3:00 - 4:30 PM | 3:00 PM - 3:20 PM | Georgia Ballrm 1- Bldg C-GWCC | Special Session | SS09 - NextGen Stars Spotlight 2: Site-Specific Cancers | Divergent resistance mechanisms to HER2-targeted therapies in breast cancer |

| | | | | | | | |
|--|---------------------------|---------------------|---|--------------------------------|--|---|--|
| F. Stephen Hodi, Arlene H. Sharpe | Ludwig Harvard | 3:00 - 5:00 PM | 3:20 PM - 3:35 PM | Room B405 - Georgia World CC | Minisymposium | MS.IM01.01 - Immune Cell Subsets in the Suppressive Tumor Microenvironment | 701 - Functionally specialized subsets of exhausted CD8+ T cells mediate tumor control and differentially respond to checkpoint blockade |
| Ivy Chen*, Rakesh K. Jain** | Ludwig Harvard | 3:00 - 5:00 PM | 3:35 PM - 3:50 PM | Room A404 - Georgia World CC | Minisymposium | MS.TB06.02 - Signaling in the Tumor Microenvironment | 2744 - Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer |
| George D. Demetri** | Ludwig Harvard | 3:00 - 5:00 PM | 4:05 - 4:20 PM | Marcus Auditorium- Bldg A-GWCC | Clinical Trials Minisymposium | CTMS02 - The Next Generation of Clinical Trials in Molecularly-driven Therapy | CT131 - Entrectinib in NTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): Integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001) |
| Roberta Zappasodi*, Cailian Liu, Xia Yang, Hong Zhong, Jingjing Qi, Philip Wong, Margaret K. Callahan, Jedd Wolchok, Taha Merghoub** | Ludwig MSK | 3:00 - 5:00 PM | 3:00 - 5:00 PM | Room A411 - Georgia World CC | Minisymposium | MS.IM02.01 - Rational Combinations of Immunotherapy | 2711 - Rational combination of GITR agonist with PD-1 blockade |
| Crystal L. Mackall | Ludwig Stanford | 3:00 - 5:00 PM | 3:35 - 3:50 PM | Room B408 - Georgia World CC | Late-Breaking Minisymposium | LBMS02 - Minisymposium: Late-Breaking Research 2 | LB-146 / 3 - Phase I CD22 CAR T-cell trial updates |
| Jedd D. Wolchok | Ludwig MSK | 5:00 - 6:30 PM | 5:00 - 6:30 PM | Hall A - Convention Center | Special Session | SS05 - Making Science Count for Patients: From T-Cell Signaling to CTLA-4 Approval | The early days of immune checkpoint inhibition: Reducing CTLA-4 blockade to clinical practice |
| Tuesday, April 2 | | | | | | | |
| Stephen J. Kron** | Ludwig Chicago | 10:30 AM - 12:15 PM | 11:35 AM - 12:00 PM | Murphy Ballrm- Bldg B- GWCC | Major Symposium | SY21 - Tumor Metabolism and DNA Damage Response | SY21-03 - Shutting off cancer's fountain of youth: Targeting metabolism to block repair and reverse immortality |
| Robert A. Weinberg | Ludwig MIT | 10:30 AM - 12:15 PM | 11:05 - 11:30 AM | Room B312 - Georgia World CC | Major Symposium | SY23 - Metastasis: Evidence and Clinical Implications of Early Dissemination | SY23-02 - Actions of the EMT Program in fostering malignant progression |
| Crystal L. Mackall | Ludwig Stanford | 10:30 AM - 12:15 PM | 10:30 - 10:31 AM | Room A402 - Georgia World CC | Major Symposium | SYPOL05 - ACCELERATE-ing Pediatric Oncology Drug Discovery and Development | Chairperson |
| Nancy E. Davidson | Ludwig Board of Directors | 1:00 - 2:45 PM | 2:05 PM - 2:30 PM | Marcus Auditorium- Bldg A-GWCC | Major Symposium | SY41-144 - Advancing Epigenetic Therapies for Solid Tumors | Prospects for epigenetic therapy for breast cancer |
| Rakesh K. Jain* | Ludwig Harvard | 1:00 - 2:45 PM | 1:00 PM - 1:01 PM and 1:05 PM - 1:30 PM | Georgia Ballrm 3- Bldg C-GWCC | Major Symposium | SY33 - Vascular Regulation of Antitumor Immunity | Chairperson and SY33-01 - Improving immunotherapy of cancer by normalizing tumor vessels |
| Sanjiv Sam Gambhir | Ludwig Stanford | 1:00 - 2:45 PM | 1:00 - 1:25 PM | Georgia Ballrm 2- Bldg C-GWCC | Advances in Diagnostics and Therapeutics | ADT16 - Tumor Treating Fields: A Fourth Modality in Cancer Treatment | Identification of a new mechanism for how tumor treating fields effect tumor cells |
| Jennifer L. Guerriero | Ludwig Harvard | 3:00 - 5:00 PM | 3:00 PM - 5:00 PM | Room A411 - Georgia World CC | Minisymposium | MS.IM02.02 - Tumor Immune Microenvironment | 4490 - PARP inhibitor efficacy depends on CD8+ T-cell recruitment via the STING pathway in BRCA-deficient models of triple-negative breast cancer |
| Jia R. Lin, Sandro Santagata, Peter K. Sorger, Alan D. D'Andrea | Ludwig Harvard | 3:00 - 5:00 PM | 3:00 PM - 5:00 PM | Room A411 - Georgia World CC | Minisymposium | MS.IM02.02 - Tumor Immune Microenvironment | 4487 - Association of the tumor-immune microenvironment with response to niraparib and pembrolizumab in relapsed, platinum-resistant ovarian cancer |
| Anthony G. Letai* | Ludwig Harvard | 3:00 - 5:00 PM | 3:00 PM - 3:01 PM | Room B312 - Georgia World CC | Minisymposium | MS.ET04.01 - Genomic Correlates of Therapy Response | Chairperson |
| Jennifer Guerriero, George Demetri, Anthony Letai** | Ludwig Harvard | 3:00 - 5:00 PM | 3:00 PM - 5:00 PM | Room B312 - Georgia World CC | Minisymposium | MS.ET04.01 - Genomic Correlates of Therapy Response | 4478 - High-throughput dynamic BH3 profiling identifies active cancer therapies in solid tumors |
| Alan D. D'Andrea | Ludwig Harvard | 3:00 - 5:00 PM | 3:05 - 3:20 PM | Marcus Auditorium- Bldg A-GWCC | Clinical Trials Minisymposium | CTMS03 - Developmental Therapeutics: Clinical Results of Novels Agents | CT232 - Phase I combination study of the CHK1 inhibitor prexasertib (LY2606368) and olaparib in patients with high-grade serous ovarian cancer and other advanced solid tumors |
| Nickolas Papadopoulos | Ludwig Johns Hopkins | 2:45 - 4:15 PM | 2:45 - 4:15 PM | Room A406 - Georgia World CC | NCI/NIH-Sponsored Session | NIH13 - Liquid Biopsy: A Holy Grail of Early Detection | Potential clinical application of liquid biopsy in early detection |
| Angelika Amon** | Ludwig MIT | 3:00 - 5:00 PM | 3:00 - 5:00 PM | Room A404 - Georgia World CC | Minisymposium | MS.EP01.01 - Factors Influencing Cancer Outcomes | 4470 - Aneuploidy drives lethal progression in prostate cancer |
| Wednesday, April 3 | | | | | | | |
| Angelika Amon | Ludwig MIT | 10:15 AM - 12:00 PM | 10:15 - 10:16 AM and 10:20 - 10:45 AM | Room B405 - Georgia World CC | Major Symposium | SY39-263 - Genomic Instability | Chairperson and The role of aneuploidy in tumorigenesis |
| Tyler Jacks | Ludwig MIT | 10:15 AM - 12:00 PM | 10:50 - 11:15 AM | Room B405 - Georgia World CC | Major Symposium | SY39-263 - Genomic Instability | Characterizing tumor evolution one cell at a time |
| Ash A. Alizadeh | Ludwig Stanford | 10:15 AM - 12:00 PM | 10:50 - 11:15 AM | Georgia Ballrm 3- Bldg C-GWCC | Major Symposium | SY06 - Novel Insights in the Molecular Pathogenesis and Monitoring of Malignant Lymphomas | Deconvoluting cellular determinants of antitumor immune recognition |

*scientist is lead author
**scientist is senior author

Ludwig Presence at 2019 AACR Annual Meeting - Poster Sessions

| Ludwig Scientist(s) | Affiliation(s) | Session Time | Presentation Time | Location | Session Type | Session Title | Presentation/Abstract Title |
|---|---------------------------|--------------------|--------------------|------------|------------------------------|--|--|
| Sunday, March 31 | | | | | | | |
| Benjamin Izar | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 PM - 5:00 PM | Section 10 | Poster Session | PO.ET01.02 - Brain Cancers and Neuroblastoma | 247 / 10 - Identification of the GABAA receptor in melanoma brain metastases patient tumors and demonstration that it is a viable drug target using benzodiazepine-derivatives |
| Peter Sorger | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 PM - 5:00 PM | Section 32 | Poster Session | PO.MCB02.01 - Apoptosis | 700 / 4 - Development of a second-generation TRAIL agonist and predictive biomarker profile for colorectal cancer |
| Jia-Ren Lin, Peter Sorger | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 PM - 5:00 PM | Section 20 | Poster Session | PO.IM01.05 - Imaging the Tumor Microenvironment | 489 / 2 - Multi-parameter tissue section imaging and retrieval of image-defined micro-regions for RNA sequencing using the RareCyte® platform |
| Jennifer Guerriero | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 PM - 5:00 PM | Section 6 | Poster Session | PO.TB06.04 - Gene Expression in the Tumor Microenvironment | 139 / 16 - Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma |
| David T. Scadden | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 PM - 5:00 PM | Section 11 | Poster Session | PO.CH01.01 - Novel Small Molecules for Cancer Therapy | 2 / 2 - Discovery of BAY 2402234 by phenotypic screening: A human Dihydroorotate Dehydrogenase (DHODH) inhibitor in clinical trials for the treatment of myeloid malignancies |
| Joan S. Brugge** | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 PM - 5:00 PM | Section 38 | Poster Session | PO.MCB11.01 - Targeting Oxidative Stress and Senescence | 884 / 10 - Interplay between NRF2 and GPX4 is critical for cancer cell survival in 3D spheroids |
| Anthony Letai | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 PM - 5:00 PM | Section 11 | Poster Session | PO.ET04.01 - Cell Death and DNA Repair Pathways | 260 / 4 - Identifying cancer drug sensitivity using live cell imaging dynamic BH3 profiling of solid tumor core biopsies |
| Anthony G. Letai | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 - 5:00 PM | Section 30 | Poster Session | PO.BSB02.01 - Convergence Science for Therapeutics and Precision Medicine | 675 / 8 - Network modeling of drug resistance mechanisms and drug combinations in breast cancer |
| Alan D. D'Andrea** | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 - 5:00 PM | Section 14 | Poster Session | PO.ET01.03 - New Anticancer Agents | 368A / 30 - Functional assessment of DNA damage repair defects and the anti-tumor immune response in high grade serous ovarian cancers using patient-derived organoids |
| Yibin Liu*, Gergana Velikova, Marketa Tomkova, Benjamin Schuster-Boeckler, Chun-Xiao Song** | Ludwig Oxford | 1:00 - 5:00 PM | 1:00 PM - 5:00 PM | Section 36 | Poster Session | PO.MCB05.04 - New Trends in DNA Methylation | 825 / 11 - TAPS: A bisulfite-free, base-resolution and quantitative sequencing method for cytosine modifications |
| Skirmantas Kriaucionis*, Marketa Tomkova, Sophie Kirschner, Mankgopo Kgatle, Richard Owen, Michael White, Benjamin Schuster-Boeckler, Xin Lu* | Ludwig Oxford | 1:00 - 5:00 PM | 1:00 PM - 5:00 PM | Section 36 | Poster Session | PO.MCB05.04 - New Trends in DNA Methylation | 835 / 21 - Altered DNA modifications in Barrett's oesophagus and oesophageal adenocarcinoma |
| Frank Furnari | Ludwig San Diego | 1:00 - 5:00 PM | 1:00 - 5:00 PM | Section 13 | Poster Session | PO.ET03.01 - Drug Resistance 1 | 331 / 22 - Dynamic kinome targeting reveals kinases involved in acquired resistance to tyrosine kinase inhibitors in EGFR-driven glioblastomas |
| Sanjiv S. Gambhir** | Ludwig Stanford | 1:00 - 5:00 PM | 1:00 - 5:00 PM | Section 10 | Poster Session | PO.ET01.02 - Brain Cancers and Neuroblastoma | 250 / 13 - Tumor treating fields increases membrane permeability in glioblastoma cells |
| Monday, April 1 | | | | | | | |
| Geoffrey Greene | Ludwig Chicago | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 2 | Poster Session | PO.EN01.01 - Endocrine-related Cancers | 1016 / 17 - The androgen receptor splice variant AR-V7 associates with the glucocorticoid receptor following androgen blockade |
| Stephen J. Kron | Ludwig Chicago | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 25 | Poster Session | PO.IM02.17 - Therapeutic Antibodies 2 | 1553 / 22 - Collagen affinity improves safety and efficacy of antibody and cytokine cancer immunotherapies |
| Marc Hafner | Ludwig Harvard | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 2 | Poster Session | PO.EN01.01 - Endocrine-related Cancers | PO.EN01.01 - Endocrine-related Cancers |
| Galit Lahav** | Ludwig Harvard | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 42 | Late-Breaking Poster Session | LBPO.MCB01 - Late-Breaking Research: Molecular and Cellular Biology / Genetics 1 | LB-101 / 21 - Combined p53 dynamics and post-translational modifications determine subsequent protein expression and cell fate |
| Cigall Kadoch | Ludwig Harvard | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 31 | Poster Session | PO.BSB01.03 - Laboratory and Computational Methods for Cancer Analysis | 1653 / 4 - Application of high-density tiling CRISPR screen technology to identify chromatin remodeler complex targets for drug discovery |
| Bradley E. Bernstein | Ludwig Harvard | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 7 | Poster Session | PO.TB07.01 - Novel Imaging Targets | 1132 / 4 - Multiplexed immunofluorescence and multispectral imaging-based quantification of tumor and immune cell populations reveals spatial relationships in oral cavity squamous cell carcinoma |
| Joan S. Brugge** | Ludwig Harvard | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 10 | Poster Session | PO.ET02.03 - Cellular Responses to Anticancer Agents 3: Novel Targets | 2978 / 26 - Clinical evaluation of lapatinib induced BCL-2 adaptive responses |
| Victor Velculescu | Ludwig Scientific Advisor | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 4 | Poster Session | PO.TB01.03 - Human in Mouse | 1065 / 16 - Comprehensive molecular and experimental characterization of ovarian clear cell carcinoma cell lines for in vivo drug development |
| Tyler Jacks** | Ludwig MIT | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 21 | Poster Session | PO.IM02.15 - Adoptive Cell Therapy 1 | TBA1431 / 12 - In vivo CRISPR/Cas9 screen of adoptively transferred T cells reveals novel mediators of T cell exhaustion and immunosuppression |
| Jedd D. Wolchok, Taha Merghoub | Ludwig MSK | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 42 | Late-Breaking Poster Session | LBPO.MCB01 - Late-Breaking Research: Molecular and Cellular Biology / Genetics | LB-081 / 1 - A nuclear cAMP microdomain functions as a tumor suppressor in melanoma |

| | | | | | | | |
|---|--|--------------------|--------------------|------------|------------------------------|---|---|
| Peter K. Sorger, Benjamin Izar** | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 PM - 5:00 PM | Section 10 | Poster Session | PO.ET02.02 - Cellular Responses to Anticancer Agents 2 / Overcoming Resistance | 2068 / 5 - A highly selective dual Haspin-kinase and PIM-inhibitor overcomes RAF/MEK-inhibitor resistance in melanoma |
| Stephen Elledge, Karen Cichowski** | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 PM - 5:00 PM | Section 40 | Late-Breaking Poster Session | LBPO.ET01 - Late-Breaking Research: Experimental and Molecular Therapeutics 1 | LB-113 / 8 - MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability inBRAF,NRASandNF1-mutant melanomas |
| Joan S. Brugge** | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 PM - 5:00 PM | Section 7 | Poster Session | PO.TB10.02 - Tumor Evolution and Heterogeneity 2 | 3775 / 8 - Characterization of intratumoral heterogeneity in drug sensitivity and modeling of drug combination effects using subclonal cell populations derived from a single breast cancer cell line |
| Myles Brown | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 - 5:00 PM | Section 37 | Poster Session | PO.MCB04.02 - Oncogenic Transcription Factor Function | 2615 / 21 - Systematic approaches to predict oncogenic transcriptional regulatory circuitries identify important nodes in high-grade serous ovarian cancer |
| Myles Brown | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 - 5:00 PM | Section 7 | Poster Session | PO.TB10.02 - Tumor Evolution and Heterogeneity 2 | 3779 / 12 - Clonal tracing reveals different mechanisms of resistance to immune checkpoint blockade |
| Anthony G. Letai** | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 - 5:00 PM | Section 32 | Poster Session | PO.MCB02.03 - BCL-2 Family Proteins | 2496 / 6 - Dynamic BH3 profiling identifies active combinations with conventional chemotherapy in non-small cell lung cancer |
| Joan S. Brugge | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 - 5:00 PM | Section 7 | Poster Session | PO.ET03.03 - Drug Resistance 3 | 2101 / 8 - Targeting the root of cancer persister cells using an expressed barcode library |
| Scott R. Manalis | Ludwig MIT | 1:00 - 5:00 PM | 1:00 - 5:00 PM | Section 30 | Poster Session | PO.BSB02.03 - Convergence Science for Tumor Biology, Molecular Biology, and Microenvironment | 2450 / 15 - Single-cell profiling reveals programs mediating oncogenic kinase-independence and minimal residual disease in BCR-ABL-rearranged acute lymphoblastic leukemia |
| Roberta Zappasodi*, Jedd D. Wolchok, Taha Merghoub** | Ludwig MSK | 1:00 - 5:00 PM | 1:00 - 5:00 PM | Section 25 | Poster Session | PO.IM02.18 - Therapeutic Antibodies 3 | 2402 / 26 - GITR cancer immunotherapy: Epitope swapping of anti-GITR TRX518 to inform functional translatability from mouse to human |
| Jorge A. Benitez*, Jianhui Ma, Tomoyuki Koga, Frank Furnari** | Ludwig San Diego | 1:00 - 5:00 PM | 1:00 - 5:00 PM | Section 40 | Late-Breaking Poster Session | Session LBPO.ET01 - Late-Breaking Research: Experimental and Molecular Therapeutics 1 | LB-110 / 5 - Proteasome addiction a new therapeutic opportunity to treat PTEN-deficient brain tumors |
| Tuesday, April 2 | | | | | | | |
| David T. Scadden | Ludwig Harvard | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 39 | Poster Session | PO.MCB08.04 - Targeting Metabolism for Cancer Therapy | 3597 / 13 - BAY 2402234: Preclinical evaluation of a novel, selective dihydroorotate dehydrogenase (DHODH) inhibitor for the treatment of diffuse large B-cell lymphoma (DLBCL) |
| Chris Sander | Ludwig Harvard | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 33 | Poster Session | PO.MCB01.05 - Cell Signaling 1 | 3451 / 22 - Interpreting gene lists from -omics experiments |
| Peter J. Park | Ludwig Harvard | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 6 | Poster Session | PO.TB08.01 - Targets and Therapies in Pediatric Cancer | 2867 / 3 - MDM2 and MDM4 are therapeutic vulnerabilities in malignant rhabdoid tumors |
| Peter Park | Ludwig Harvard | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 25 | Poster Session | PO.IM02.11 - Novel Immunomodulatory Agents 1 | 3257 / 7 - Activation of CD137 using multivalent and tumor targeted Bicyclic peptides |
| Anthony Letai** | Ludwig Harvard | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 11 | Poster Session | PO.ET01.07 - Diagnostics, Biomarkers, and the Tumor Microenvironment | 2990 / 12 - Individualized functional approach to tailoring acute myeloid leukemia therapy |
| Danny Khail | Ludwig MSK | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 42 | Late-Breaking Poster Session | LBPO.IM02 - Late-Breaking Research: Immunology 2 | LB-194 / 12 - First-in-human Phase I study of the CD40 agonist mAb CDX-1140 and in combination with CDX-301 (rFLT3L) in patients with advanced cancers: Interim results |
| Frank Furnari | Ludwig San Diego | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 12 | Poster Session | Session PO.ET03.04 - Drug Resistance 4 | 3019 / 11 - Dynamic kinome profiling of EGFRvIII-driven murine astrocyte models of glioblastoma reveals targets for dual kinase inhibitor therapy |
| Marc A. Hafner, Peter K. Sorger** | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 PM - 5:00 PM | Section 37 | Poster Session | PO.MCB06.02 - Targeting the Cell Cycle: Development of Preclinical Models and Therapeutic Targets | 4432 / 26 - Multi-omics profiling establishes the polypharmacology of FDA Approved CDK4/6 inhibitors and its impact on drug response |
| Chris Sander | Ludwig Harvard | 1:00 - 5:00 PM | 1:00 PM - 5:00 PM | Section 10 | Poster Session | PO.ET03.05 - Drug Resistance 5 | 3820 / 25 - Discovery of adaptive resistance pathways and anti-resistance combination therapies from phosphoproteomic data using graphical models |
| Matthew Vander Heiden | Ludwig MIT | 1:00 - 5:00 PM | 1:00PM - 5:00 PM | Section 35 | Poster Session | PO.MCB08.03 - Metabolic Reprogramming in Cancer | 4358 / 6 - Characterization of primary and metastatic pancreatic tumors in pancreatic ductal adenocarcinoma (PDAC) |
| Jedd Wolchok, Taha Merghoub, Sadna Budhu | Ludwig MSK | 1:00 - 5:00 PM | 1:00PM - 5:00 PM | Section 5 | Poster Session | PO.TB09.02 - Radiation Tissue Tolerance, Immunity, and in Vivo Effects of Radiation | 3735 / 12 - An anti-tumor immune response is evoked by partial-volume single dose radiation |
| Taha Merghoub, Jedd D. Wolchok, Victor E. Velculescu | Ludwig MSK + Ludwig Scientific Advisor | 1:00 - 5:00 PM | 1:00PM - 5:00 PM | Section 22 | Poster Session | PO.IM02.09 - Biomarkers and Immune Monitoring | 4041 / 4 - Coupling neoantigen specific T cell clonotypes and their molecular phenotypes at the single cell level in resectable anti-PD-1 treated NSCLC |
| Yang Li | Ludwig San Diego | 1:00 - 5:00 PM | 1:00PM - 5:00 PM | Section 33 | Poster Session | Session PO.MCB05.02 - Epigenetic Changes as Molecular Markers | 4334 / 22 - Epigenetic reprogramming of tissue-specific transcription promotes metastasis |
| Victor Velculescu** | Ludwig Scientific Advisor | 1:00 - 5:00 PM | 1:00 - 5:00 PM | Section 41 | Late-Breaking Poster Session | LBPO.CL02 - Late-Breaking Research: Clinical Research 2 | LB-231 / 10 - Genome-wide cell-free DNA fragmentation as a biomarker for early detection of cancer |
| Victor Velculescu | Ludwig Scientific Advisor | 1:00 - 5:00 PM | 1:00 - 5:00 PM | Section 19 | Poster Session | PO.CL11.06 - Novel Strategies for Biomarker Identification and Use in Cancer 2 | 3977 / 3 - Clinical validation of cell-free circulating tumor DNA to detect therapy resistance and disease progression in metastatic colorectal cancer patients |
| Victor Velculescu | Ludwig Scientific Advisor | 1:00 - 5:00 PM | 1:00 - 5:00 PM | Section 22 | Poster Session | PO.IM02.09 - Biomarkers and Immune Monitoring | 4041 / 4 - Coupling neoantigen specific T cell clonotypes and their molecular phenotypes at the single cell level in resectable anti-PD-1 treated NSCLC |

*scientist is lead author
**scientist is senior author

| Wednesday, April 3 | | | | | | | |
|--|----------------------------|--------------------|--------------------|------------|----------------|--|---|
| Stephen J. Kron** | Ludwig Chicago | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 10 | Poster Session | PO.ET06.08 - DNA Repair and Reactive Agents / HDAC / Demethylating Agents | 4738 / 28 - Lipid peroxidation mediates the effects of topoisomerase poisons on their targets |
| Sheheryar Kabraji | Ludwig Harvard | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 14 | Poster Session | PO.ET07.01 - Targeted Therapies | 4832 / 20 - Preclinical evaluation of neratinib plus T-DM1 in orthotopic PDX models of HER2-positive breast cancer brain metastases |
| Anthony Letai, Michael Hemann | Ludwig Harvard, Ludwig MIT | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 35 | Poster Session | PO.MCB05.03 - Deregulation of Histone Modifications | 5186 / 4 - Discovery of a novel histone deacetylase 6 inhibitor that kills drug-resistant breast cancer |
| Jon Aster | Ludwig Harvard | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 19 | Poster Session | PO.CL11.07 - Novel Strategies for Biomarker Identification and Use in Cancer 3 | 4885 / 8 - AL101 mediated tumor inhibition in Notch mutated ACC PDX models |
| David Benjamin | Ludwig MIT | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 30 | Poster Session | PO.BSB01.05 - Methods and Tools for Cancer Analysis | 5108 / 16 - Somatic small variant and copy number alteration calling with the Genome Analysis Toolkit |
| Marketa Tomkova* | Ludwig Oxford | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 7 | Poster Session | PO.TB11.01 - Mutagenesis, Chemical Carcinogenesis, and Tumor Initiation/Promotion | Deciphering the causes of the COSMIC mutational signature 17 by combining pan-cancer data with experimental mouse models |
| Arnab Ghosh*, Hong Zhong, Sadna Budhu, Jedd Wolchok, Taha Merghoub** | Ludwig MSK | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 15 | Poster Session | PO.ET07.03 - Targeted Therapies and Immunological/Tumor Microenvironment Effects | 4843 / 1 - TP53-stabilization with APR-246 enhances antitumor effects of immune checkpoint blockade in preclinical models |
| Ravindra Majeti** | Ludwig Stanford | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 32 | Poster Session | PO.MCB09.07 - Advanced Omics | 5130 / 9 - Single-cell mutational profiling of paired AML samples at diagnosis, remission and relapse: Implications for therapeutic resistance and MRD detection |
| Sanjiv S. Gambhir** | Ludwig Stanford | 8:00 AM - 12:00 PM | 8:00 AM - 12:00 PM | Section 38 | Poster Session | PO.MCB08.05 - Tracking Metabolic Profiles and Subtype-specific Metabolic Interventions | 5271 / 14 - Molecular imaging of pyruvate kinase M2 (PKM2) with [18F]DASA-23 detects temozolomide- and tumor treating fields (TTFields)-induced changes in glycolysis in glioblastoma |